Skip to main navigation Skip to search Skip to main content

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

  • Geoffrey L. Uy
  • , Ibrahim Aldoss
  • , Matthew C. Foster
  • , Peter H. Sayre
  • , Matthew J. Wieduwilt
  • , Anjali S. Advani
  • , John E. Godwin
  • , Martha L. Arellano
  • , Kendra L. Sweet
  • , Ashkan Emadi
  • , Farhad Ravandi
  • , Harry P. Erba
  • , Michael Byrne
  • , Laura Michaelis
  • , Max S. Topp
  • , Norbert Vey
  • , Fabio Ciceri
  • , Matteo Giovanni Carrabba
  • , Stefania Paolini
  • , Gerwin A. Huls
    • Mojca Jongen-Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Récher, Patrick J. Stiff, Kristen M. Pettit, Bob Löwenberg, Sarah E. Church, Erica Anderson, Jayakumar Vadakekolathu, Marianne Santaguida, Michael P. Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, Kathy Tran, Patrick Kaminker, Maya Kostova, Ezio Bonvini, Roland B. Walter, Jan K. Davidson-Moncada, Sergio Rutella, John F. DiPersio

Research output: Contribution to journal › Article › peer-review

295   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology